Molecular Formula | C17H13Cl2NO4 |
Molar Mass | 366.2 |
Density | 1.456 |
Melting Point | 149-151℃ |
Boling Point | 608.9±55.0 °C(Predicted) |
pKa | 10.43±0.20(Predicted) |
Storage Condition | Store at -20° C. |
In vitro study | YK-4-279 eliminates cyclin D levels by blocking the interaction of EWS-FLI1 with RHA in EWS-FLI1-containing TC32 cells. YK-4-279 also specifically inhibits ESFT cell growth and induces apoptosis. YK-4-279 also inhibits ERG and ETV1 biological activity in fusion-positive prostate cancer cells, and further decreases cell motility and invasion. |
In vivo study | In vivo, YK-4-279 (1.5 mg/dose i.p.) inhibits the growth of ESFT xenograft tumors. In mouse model, YK-4-279 selectively prevents prostate cancer growth and metastasis in fusion-positive LNCaP-luc-M6 tumors. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.731 ml | 13.654 ml | 27.307 ml |
5 mM | 0.546 ml | 2.731 ml | 5.461 ml |
10 mM | 0.273 ml | 1.365 ml | 2.731 ml |
5 mM | 0.055 ml | 0.273 ml | 0.546 ml |